References
- Manson JE, Chlebowski RT, Stefanick MI, et al. Menopausal therapy and health outcomes during the intervention and postintervention and extended poststopping phases of the Women's Health Initiative randomized controlled trials. JAMA 2013;1353–68
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
- Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939–45
- Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023–8
- Shapiro S, de Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric 2014;17:215–22
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047–59
- Shapiro S, Farmer RD, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011;37:103–9